Caixin
Caixin Global – Latest China News & Headlines

Home >

TRENDING
Pony AI, WeRide Seek to Raise Combined $1.3 Billion in Hong Kong
MiniMax Unveils M2 Model to Compete on Speed and Cost
Tech Brief (Oct. 27): Huawei EV Partner Seres Unveils Hong Kong IPO Plan
LATEST
MiniMax Unveils M2 Model to Compete on Speed and Cost
Pony AI, WeRide Seek to Raise Combined $1.3 Billion in Hong Kong
Tech Brief (Oct. 28): Meituan Releases Open-Source Video Generation Model
Tech Brief (Oct. 27): Huawei EV Partner Seres Unveils Hong Kong IPO Plan
Tech Brief (Oct. 24): China Vows to Accelerate Tech Self-Reliance
Tech Brief (Oct. 23): China Cracks Down on Smart Devices Over Data Violations
Chinese Firms Urged to Fortify Online Brands as Cybersquatting Costs Mount
Tech Brief (Oct. 16): China’s Tech Minister Meets With Apple CEO
China Debuts Ultrafast Oscilloscope in Drive to Break Tech Barriers
Tech Brief (Oct. 15): Google to Invest $15 Billion in India for AI Hub
Tech Brief (Oct. 13): Wingtech Temporarily Loses Control of Dutch Chipmaker Nexperia
Tech Brief (Oct. 10): China’s AI Server Market Doubles
Tech Brief (Oct. 9): SoftBank to Acquire ABB’s Robotics Business
Tech Brief (Sept. 30): U.S. Widens Export Blacklist
U.S. Tightens Export Controls to Cover Subsidiaries of Blacklisted Firms
DeepSeek Unveils New Model With Sparse Attention, Slashes API Costs
Tech Brief (Sept. 29): Meituan’s Food-Delivery Platform Keeta Launches in Dubai
Chinese Chipmaker Moore Threads Gets Fast Track Approval to $1.1 Billion IPO
Chinese Drone Maker XAG Files for Hong Kong IPO After First Annual Profit
GPT Weekly: Nvidia to Invest $100 Billion in OpenAI

By Ren Qiuyu / Nov 27, 2018 05:25 PM / Society & Culture

Researcher He Jiankui (right). Photo: VCG

Researcher He Jiankui (right). Photo: VCG

A major international summit on gene editing opened Tuesday in Hong Kong under the shadow of a recent scandal: Researcher He Jiankui claimed Monday to have edited genes in embryos to make them resistant to HIV, causing uproar from the international scientific and academic communities.

Feng Zhang, one of the founders of the CRISPR Cas9 technology used in He’s experiment and a professor at MIT, told Caixin that DNA editing has a long way to go before being used in embryos.

“Fundamentally, I don’t think genome editing is ready to be applied in embryos for implantation purposes. There are still technical hurdles we have to solve,” he said.

He also expressed outrage that the babies had been exposed to unnecessary risks. “There is a standard protocol for treating the mother who is not HIV-positive,” Zhang said. “Given that you already have an established and safe procedure, to expose the child to this level of risk is completely unnecessary and irresponsible.”

Zhang also issued a statement Monday calling for a moratorium on genetic editing of human embryos until comprehensive safety measures were introduced.


Share this article
Open WeChat and scan the QR code